Technical Analysis for OLMA - Olema Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | N/A |
| Historical OLMA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Hot IPO Pullback | Bullish Swing Setup | 0.61% | |
| Multiple of Ten Bearish | Other | 0.61% | |
| New 52 Week Closing Low | Bearish | 5.71% | |
| Multiple of Ten Bearish | Other | 5.71% | |
| Inside Day | Range Contraction | 5.71% | |
| New 52 Week Closing High | Bullish | -5.65% | |
| New 52 Week High | Strength | -5.65% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Up 3% | 3 days ago | |
| Up 2% | 3 days ago | |
| Gap Down Closed | 3 days ago | |
| Up 1% | 3 days ago | |
| Reversed from Down | 3 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
Medicine Biopharmaceutical Clinical Medicine Breast Cancer Hormones Targeted Therapy Her2/Neu Antiestrogens Selective Estrogen Receptor Degraders Estrogen Fulvestrant
Medicine Biopharmaceutical Clinical Medicine Breast Cancer Hormones Targeted Therapy Her2/Neu Antiestrogens Selective Estrogen Receptor Degraders Estrogen Fulvestrant
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 56.4322 |
| 52 Week Low | 40.0 |
| Average Volume | 532,686 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 0.00 |
| Average True Range | 0.00 |
| ADX | 0.0 |
| +DI | 0.00 |
| -DI | 0.00 |
| Chandelier Exit (Long, 3 ATRs ) | N/A |
| Chandelier Exit (Short, 3 ATRs ) | N/A |
| Upper Bollinger Band | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 54.81 | ||||
| Resistance 3 (R3) | 54.77 | 53.06 | 53.98 | ||
| Resistance 2 (R2) | 53.06 | 51.78 | 53.08 | 53.70 | |
| Resistance 1 (R1) | 51.43 | 51.00 | 52.25 | 51.47 | 53.42 |
| Pivot Point | 49.72 | 49.72 | 50.13 | 49.74 | 49.72 |
| Support 1 (S1) | 48.09 | 48.44 | 48.91 | 48.13 | 46.18 |
| Support 2 (S2) | 46.38 | 47.66 | 46.40 | 45.90 | |
| Support 3 (S3) | 44.75 | 46.38 | 45.63 | ||
| Support 4 (S4) | 44.79 |
